The fourth industrial revolution is upon us. Also known as "Industry 4.0" or "4IR," it takes the technological advances of the third industrial revolution and connects them into systems that can often operate and adapt without human input. New technologies can create exciting possibilities for positive social impact on diverse issues such as income inequality and the environment.

Yet, at the same time, they often raise new, sometimes difficult, ethical questions. In fact, the irony is this: As we develop technologies that adapt without human input, we are discovering we need human input to address what constitutes the ethical use of these technologies.

As mentioned in a Deloitte article, most leaders want their organizations to create social impact. In today's competitive business environment, social impact initiatives have the ability to separate one company from its competitors in the eyes of consumers. The logic that a company "does well by doing good" has taken hold. And 4IR technologies promise to support companies' efforts to reduce carbon emissions, support diversity initiatives, and other social impact goals.

Yet some leaders are also recognizing that 4IR technologies raise ethical questions in areas such as data privacy, algorithmic bias, and potentially a lack of inclusivity in technology design.

According to Deloitte Global CEO Punit Renjen's report, "Success Personified in the Fourth Industrial Revolution," which is based on a Forbes Insights survey, C-suite executives have varying levels of concern about using technology ethically. From June-August 2018, Forbes Insights surveyed 2,042 executives (with company revenue of $1 billion or more) and public sector leaders (with organization budgets of $500 million or more) from 19 countries and all major industry sectors.

As shown in Figure 2 below, only 15 percent of the 194 CEOs/presidents surveyed are strongly concerned about ethical technology use. Surprisingly, chief information officers and chief technology officers are also at the lower end of the spectrum, at 16 percent and 17 percent, respectively. On the other hand, 41 percent of chief operating officers, 41 percent of chief digital officers, and 50 percent of chief sustainability officers are strongly concerned about ethical technology use.

This disparity in levels of concern about ethical technology use at the top of the organization often results in lack of clarity throughout the rest of the organization. Deloitte offers three recommendations to address this:

  • 1. C-Suite adoption: The CEO must prioritize ethical technology use and encourage the rest of the C-suite to do so too.
  • 2. Culture change: The C-suite must set, model, and communicate ethical use of technology and encourage buy-in from employees by allowing them to share ideas about ethical technology use.
  • 3. Adapt: As technology continues to change, companies must continue to define how to use it ethically.

Ethics are important in and of themselves. However, there may also be business benefits for prioritizing ethical use of technology.

As shown in Figure 1 below, Deloitte's analysis of the Success Personified report found a correlation between high concern for ethical use of 4IR technologies and business growth. Of the 536 respondents whose organizations had 0 percent growth, only 17 percent of them strongly agreed that their organization is highly concerned with ethically using 4IR technologies.

On the other hand, of the 148 respondents whose organizations had 10 percent or more growth, 55 percent of them strongly agreed that their organization is highly concerned with ethically using 4IR technologies.

As more companies aim to make a social impact, C-suite leaders should consider the ethics of 4IR technology implementation to grow as a business and stand out among competitors.

---

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice University lands $18M to revolutionize lymphatic disease detection

fresh funding

An arm of the U.S. Department of Health and Human Services has awarded $18 million to scientists at Rice University for research that has the potential to revolutionize how lymphatic diseases are detected and help increase survivability.

The lymphatic system is the network of vessels all over the body that help eliminate waste, absorb fat and maintain fluid balance. Diseases in this system are often difficult to detect early due to the small size of the vessels and the invasiveness of biopsy testing. Though survival rates of lymph disease have skyrocketed in the United States over the last five years, it still claims around 200,000 people in the country annually.

Early detection of complex lymphatic anomalies (CLAs) and lymphedema is essential in increasing successful treatment rates. That’s where Rice University’s SynthX Center, directed by Han Xiao and Lei Li, an assistant professor of electrical and computer engineering, comes in.

Aided by researchers from Texas Children’s Hospital, Baylor College of Medicine, the University of Texas at Dallas and the University of Texas Southwestern Medical Center, the center is pioneering two technologies: the Visual Imaging System for Tracing and Analyzing Lymphatics with Photoacoustics (VISTA-LYMPH) and Digital Plasmonic Nanobubble Detection for Protein (DIAMOND-P).

Simply put, VISTA-LYMPH uses photoacoustic tomography (PAT), a combination of light and sound, to more accurately map the tiny vessels of the lymphatic system. The process is more effective than diagnostic tools that use only light or sound, independent of one another. The research award is through the Advanced Research Projects Agency for Health (ARPA-H) Lymphatic Imaging, Genomics and pHenotyping Technologies (LIGHT) program, part of the U.S. HHS, which saw the potential of VISTA-LYMPH in animal tests that produced finely detailed diagnostic maps.

“Thanks to ARPA-H’s award, we will build the most advanced PAT system to image the body’s lymphatic network with unprecedented resolution and speed, enabling earlier and more accurate diagnosis,” Li said in a news release.

Meanwhile, DIAMOND-P could replace the older, less exact immunoassay. It uses laser-heated vapors of plasmonic nanoparticles to detect viruses without having to separate or amplify, and at room temperature, greatly simplifying the process. This is an important part of greater diagnosis because even with VISTA-LYMPH’s greater imaging accuracy, many lymphatic diseases still do not appear. Detecting biological markers is still necessary.

According to Rice, the efforts will help address lymphatic disorders, including Gorham-Stout disease, kaposiform lymphangiomatosis and generalized lymphatic anomaly. They also could help manage conditions associated with lymphatic dysfunction, including cancer metastasis, cardiovascular disease and neurodegeneration.

“By validating VISTA-LYMPH and DIAMOND-P in both preclinical and clinical settings, the team aims to establish a comprehensive diagnostic pipeline for lymphatic diseases and potentially beyond,” Xiao added in the release.

The ARPA-H award funds the project for up to five years.

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.